JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo chimeric antigen receptor T-Cell (CAR-T cell) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."